# A Role of p38 MAP Kinase Inhibitor (sb239063) and Vit B12 Against Neuroinflammation.

**Ashish Kumar Verma*[1], Mamta F Singh[2]**

[1]Department of pharmacology, teerthanker Mahaveer College of pharmacy, teerthanker Mahaveer University, Moradabad, India.

[2]Department of pharmacology, sardar bhagwan singh university, Dehradun, India.

## Abstract

**Back ground: The objective of this work was to study the effect of p38 MAP Kinase inhibitor (SB239063) and Vit B12 on activity of p38 MAP kinase implicated in neuroinflammation. In the central nervous system (CNS) neuroinflammatin is a common feature of age-related neurodegenerative diseases. Proinflammatory cytokines, such as IL-1β and TNFα, are produced primarily by cells of the innate immune system, namely microglia in the CNS, and are believed to contribute to the neuronal damage seen in the disease. The p38 mitogen-activated protein kinase (MAPK) is one of the kinase pathways that regulate the production of IL-1β and TNFα. Recent studies suggest that vitamin B12, in addition to its known role as a co-factor in myelin formation, has important immunomodulatory and neurotropic effects.**

**Material and methods: Male wistar albino rats (weighing about 100-200gm) were obtained from animal house of institute divided in to eight groups each group having six animals. Neuroinflammation was induced in animals by the LPS (100µg/ml) fallowed by treatment with MAPK inhibitor (SB239063) alone (5mg/kg) and along with Vit B12 (0.5mg/kg) for 30 days.**

**Result and conclusion: In the present study initially behavioral models (elevated plus maze apparatus, Morris water maze apparatus) were used to evaluate the memory of neuroinflammed rats which were followed by biochemical analysis. On the basis of result obtained from present study, it is observed that p38 MAPK inhibitor (SB239063) alone and in combination with Vitamin B12 is a novel therapeutic target for neuroinflammatory diseases.**

**Keywords:** P38MAPK, Neuroinflammation,Vitamin B12, Neurodegenerative diseases, Proinflammatory , cytokines.

*Accepted on 06 January, 2022*

## Introduction

Since Inflammation in the central nervous system (CNS) is a common feature of age-related neurodegenerative diseases .Cytokines is one of the primary classes of inflammatory mediators throughout the body, including the central nervous system (CNS). Signaling molecules that act through specific receptors and signal transduction pathways to exert a particular biological response in a target cell are cytokines. Extensive evidence from both preclinical studies and clinical animal models has showed that overproduction of proinflammatory cytokines as a contributor to pathophysiology progression in chronic neurodegenerative disorders like Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis.[1] There are specific class of serine/ threonine kinases which respond to extracellular signals such as growth factors, mitogens, and cellular stress and mediate proliferation, differentiation, and cell survival in mammalian cells.MAPKs are of four different groups within mammalian cells: the extracellular signal-related kinases (ERKs), the c-jun Nterminal kinases (JNKs), the atypical MAPKs (ERK3, ERK5, and ERK8), and the p38 MAPKs.[2] The p38 MAPKs are known as stress-activated protein kinases as they are primarily activated through extracellular stresses and cytokines and consequently have been extensively studied in the field of inflammation.Some additional roles of p38 MAPK which are becoming of interest, including the role that the p38 MAPK signalling pathway plays in neuronal function such as synaptic plasticity and neurodegenerative disease. Vitamin B12 is an important micronutrient which is required in various biological processes.[3] It act as a coenzyme in folate metabolism and nucleotide biosynthesis, which makes it crucial in the metabolism of fatty acids and some amino acids and normal nervous system function.[4] Furthermore, vitamin B12 deficiency results in methionine deficiency, leading to the dyes-synthesis of both phospholipids and myelin.[5] Currently, combination therapy with vitamin B12 is widely combined and used in clinical patients with nerve diseases. It has been reported that systemic administration of vitamin B12 promoted the recovery process from peripheral nerve damage in experimental rats.[6] Additionally, vitamin B12 was recently shown to be a superoxide scavenger contributing to neuronal cells axonal growth.7 Thus, we hypothesized that vitamin B12 could enhance axon formation after neuroinflammation via stabling microtubule and reducing neuronal apoptosis. One class of p38 MAPKs inhibitor compounds, the pyridinyl imidazoles (originally named CSAIDs for "cytokine-suppressive anti-inflammatory drugs"), have well characterized therapeutic utility related to their inhibition of TNFa and

interleukin-1beta production.[8-12] This can reduce inflammation, including the expression of other inflammatory mediators/proteins, thus significantly affecting the ultimate degree of tissue injury. CSAIDs inhibit the catalytic activity of activated/phosphorylated p38 to phosphorylate MAPKAP-K2, which upon activation serves in nuclear import/export of p38 (and itself) and provides for the phosphorylation of downstream substrates (e.g., Hsp27 for MAPKAP-K2) in the cytoplasm.[13] Not only does p38 phosphorylation/activation phosphorylate transcription factors (e.g., ATF2), it can also up-regulate protein transcription and translation and stabilize mRNA.[14] Abundant evidences exist demonstrating that neuroinflammation contributes to the pathogenesis of several neurodegenerative disorders. This is also strengthened by epidemiological and clinical studies showing a possible protective effect of MAP kinase inhibitor (SB239063) against various inflammatory diseases like rheumatoid arthritis (RA), and inflammatory bowel disease (IBD), crohn's disease (CD).It also been seen that Vit B12 (cyanocobalamine) act as a co-factor in myelin formation, has important immunomodulatory and neurotropic effects.

## Material and Methods

### *Materials*

**Animals:** Male albino wistar rats (2.5 month old,weighing about 100-200 gm) were used for the study. The animal were housed in standard polypropylene cages and maintained under controlled room temperature (22C +20C) and relative humidity (55+5%) with 12:12 hour light and dark cycle. All the animals were providing with commercially available normal pellet diet and water. The animals were acclimatized to laboratory conditions before behavioral experiments that were carried out between 09:00 and 17:00 h. The experimental protocol was approved by the institutional animal ethics committee, the guidelines of the Committee for the purpose of Control and Supervision of Experiments on Animals (CPCSEA) Registration no. 1446/PO/a/11/CPCSEA of the Govt. of India was followed and prior permission will be granted from the Institutional Animal Ethics Committee for conducting the experimental studies.

**Chemicals:** All other chemicals and reagents used which were of analytical grade were products of Sigma Aldrich Ltd., Medchemexpress and are prepared in volumetric flask using glass wares with distilled water.

### *Methods*

**Behavioral methods:** In this study we were using two behavioral models namely Elevated plus maze apparatus, Morris Water Maze apparatus.

**Biochemical estimations:** After evaluation of behavioral test, animals were fasted overnight and blood was taken from the retro orbital plexus under mild ether anesthesia, serum was separated and used for the estimation of various biochemical parameters.

**Animal grouping and treatment protocol:** The animals will be divided into eight groups each containing six animals and group 1 of normal animals will receive the vehicle normal saline at a dose of 1 ml/kg, p.o., Group 2nd is diseased control group receiving LPS (100 µgm/kg, I.P.) on 1st,7th,14th,21th and 30th day of study. Rest all groups are test groups. Group 3 received LPS (100 µgm/kg, I.P.) on 1st, 7th, 14th, 21th and 30th day of study +MAP kinas inhibitor, SB239063 (5 mg/kg,I.V.) on 21st to 30 th day of study. Group 4 received received LPS (100 µgm/kg, I.P.) on 1st, 7th, 14th,21th and 30th day of study + Vit B12 alone (0.5 mg/kg P.O.) on 21st to 30 th day of study. Group 5 received Test group received received LPS (100 µgm/kg, I.P.) on 1st, 7th, 14th, 21th and 30th day of study + SB239063 (2.5 mg/kg, I.V) + Vit B12 (0.5 mg/kg P.O.) on 21st to 30 th day of study. Group 6 received received received LPS (100 µgm/kg, I.P.) on 1st, 7th, 14th, 21th and 30th day of study + SB239063 (2.5 mg/kg, I.V) + Vit B12 (0.5 mg/kg P.O.) on 21st to 30 th day of study. Group 7 received received LPS (100 µgm/kg, I.P.) on 1st, 7th, 14th, 21th and 30th day of study + SB239063 (2.5 mg/kg, I.V) + Vit B12 (0.5 mg/kg P.O.) on 21st to 30 th day of study. Group 8 is Standard control received received LPS (100 µgm/kg, I.P.) on 1st, 7th, 14th, 21th and 30th day of study + Donepazil (1 mg/kg, PO).

## Data analysis

Data were expressed as the mean ± SD of 9 determinations. Statistical analysis was performed using one-way Analysis of Variance (ANOVA) fallowed by tukey multiple comparison test. Data were considered statistically significant at $p<0.05$. All these analyses were done using Graph prism pad 7.03 Software.

## Results

In the present study initially behavioral models (elevated plus maze apparatus, Morris water maze apparatus) were used to evaluate the memory of neuroinflammed mice which were followed by biochemical analysis.

**Effect of SB239063 and its combination with Vit B12 at different doses levels on the transfer latency in the LPS induced neuroinflammation in rats using elevated plus maze apparatus:** Results of present study are summarized in the table 1 Results of the table reveal that administration of LPS(100µg/kg,i.p.) on 1st,7th,14th,21st,30th days caused significant increase ($p<0.01$) in transfer latency in all group.Treatment of the neuroinflammed rats by compound SB239063 from 21st to 30th day of study caused marked decrease in transfer latency (51.2±2.28), (57.0±4.00), (69.0±1.58), (65.4±2.60), (55.2±2.16) as compared to the LPS treated rats (51±2.23),(58.0±2.91) (68.8±1.92) (79.0±1.58) (86.0±2.34). Adminstration of the combination of SB239063 at a dose of 4.5 mg/kg along with vit. B12 at a dose of 0.5 mg/kg also caused significant reduction (51.0±2.72),(53.8±2.28) as compared to LPS treated animals.Vit b12 given alone and combination of compound SB239063 and Vit B12 at a dose of 3.5 mg/kg and 0.5 mg/kg also caused moderate decrease in the ($p<0.01$) in neuroinflammed rats however combination of

compound SB239063B12 at a dose of 2.5 mg/kg does not cause any significant decrease in the transfer latency in neurotonic rats. The standard drug donepezil also provided maximum protection in neuroinflammation in LPS treated rats. Results indicates that the compound SB239063 at a dose of 5 mg/kg, i.p,alone and combination of SB239063 at a dose of 4.5mg/kg,ip.,+0.5 mg/kg,.po.,caused maximum improvement in T.L. and memory in neuroinflammed rats.

*Table 1. Effect of sb239063 on the transfer latency in lps induced neuroinflammation in rats by using elevated plus maze apparatus.*

| Treatment | Transfer latency on day 1 (Sec.) | Transfer latency on day 7(Sec.) | Transfer latency on day 14(Sec.) | Transfer latency on day 21(Sec.) | Transfer latency on day 30th(Sec.) |
|---|---|---|---|---|---|
| Group 1 | 49.8 ±1.78 | 50.8 ±1.92 | 50.8 ±1.92 | 50.8 ± 1.92 | 50.8 ± 1.92 |
| Group 2 | 51 ± 2.23 | 58.0 ±2.91* | 68.8 ± 1.92* | 79.0 ± 1.58* | 86.0 ± 2.34* |
| Group 3 | 51.2 ± 2.28 | 57.0 ± 4.00* | 69.0 ± 1.58* | 65.4 ± 2.60* | 55.2 ± 2.16* |
| Group 4 | 51.8 ± 2.27 | 58.0 ± 2.91* | 69.4 ± 1.67* | 67.8 ± 2.16* | 63 ± 1.87* |
| Group 5 | 51.± 2.72 | 57.8 ± 3.27* | 68.4 ± 4.97* | 62.4 ± 2.30* | 58.8 ± 2.28* |
| Group 6 | 50.6 ±1.67 | 58.6 ± 3.20* | 68.2 ± 4.91* | 66.8 ± 1.48* | 60.6 ± 2.30* |
| Group 7 | 50.4 ±1.81 | 54.8 ± 5.35* | 68.0 ± 2.91* | 77.4 ± 2.30* | 69.4 ± 1.94* |
| Group 8 | 50.6 ±1.49 | 55.0 ± 5.56* | 70.0 ±1.87* | 63.6 ± 1.67* | 50.2 ± 2.58* |

**Effect of SB239063 and its combination with Vit B12 at different doses levels on the time spent in target quartent (T.S.T.Q.) in the LPS induced neuroinflammation in rats using Morris water maze apparatus:** Results of present study are summarized in the table 2 Results of the table reveal that administration of LPS(100µg/kg,i.p.) on 1st,7th,14th,21st,30th days caused significant decrease ($p<0.01$) in T.S.T.Q. in all group.Treatment of the neuroinflammed rats by compound SB239063 from 21st to 30th day of study caused marked increase in T.S.T.Q. (26.8±2.04), (31.6±2.07) as compared to the LPS treated rats (29.4±1.34), (27.2±3.03), (23.8±2.04), (22.8±1.78),(19.6±2.07). Adminstration of the combination of SB239063 at a dose of 4.5 mg/kg along with vit. B12 at a dose of 0.5 mg/kg also caused significant increase (24.4±1.51) , (29.8±2.95) as compared to LPS treated animals.Vit b12 given alone and combination of compound SB239063 and Vit B12 at a dose of 3.5mg/kg and 0.5 mg/kg also caused moderate increase in the T.S.T.Q. in neuroinflammed rats however combination of compound SB239063B12 at a dose of 2.5 mg/kg does not cause any significant increase in the T.S.T.Q. in neurotonic rats. The standard drug donepezil also provided maximum protection in neuroinflammation in LPS treated rats. Results indicates that the compound SB239063 at a dose of 5 mg/kg,i.p.,alone and combination of SB239063 at a dose of 4.5mg/kg,ip.,+0.5mg/kg,.po.,caused maximum improvement in T.S.T.Q. and memory in neuroinflammed rats.

*Table 2. Effect of sb239063 on the time spent in target quartent in lps induced neuroinflammation in rats by using morris water maze apparatus.*

| Treatment | Time spent in target quartent(T.S.T.Q.) on day 1(Sec.) | Time spent in target quartent(T.S.T.Q.) on day 7(Sec.) | Time spent in target quartent(T.S.T.Q.) on day 14(Sec.) | Time spent in target quartent(T.S.T.Q.) on day 21(Sec.) | Time spent in target quartent(T.S.T.Q.) on day 30th(Sec.) |
|---|---|---|---|---|---|
| Group 1 | 28.8 ± 1.64 | 30.2 ± 2.28 | 29.0 ± 1.00 | 28.8 ± 1.78 | 30.6 ± 1.81 |
| Group 2 | 29.4 ± 1.34 | 27.2 ± 3.03 | 23.8 ± 2.04* | 22.8 ± 1.78* | 19.6 ± 2.07* |
| Group 3 | 28.8 ± 1.30 | 28.6 ± 2.40 | 24.2 ± 1.64* | 26.8 ± 2.04* | 31.6 ± 2.07* |
| Group 4 | 29.0 ± 1.00 | 28.4 ± 2.70 | 23.8 ± 1.92* | 24.4 ± 1.51* | 26.6 ± 2.07* |
| Group 5 | 28.6 ±1.34 | 27.8 ± 2.04 | 23.2 ± 2.38* | 26.2 ± 1.02* | 29.8 ± 2.95* |
| Group 6 | 29.4 ± 0.89 | 27.8 ± 2.58 | 23.4 ± 1.67 | 26.0 ± 1.87 | 25.4 ± 2.19* |
| Group 7 | 29.8 ± 1.09 | 28.2 ± 2.16 | 24.2 ± 2.38* | 24.2 ± 2.28* | 24.8 ± 2.49* |
| Group 8 | 28.2 ± 1.30 | 28.2 ± 2.16 | 24.6 ± 1.81 | 28.0 ± 2.34* | 33.8 ± 2.04* |

**Effect of SB239063 and its combination with Vit B12 at different doses levels on the blood level of cholesterol in LPS induced neuroinflammation in rats:** Literature from the previous studies reveals that LPS causes activation of microglial cells as well as activation of inflammatory mediators and hypercholesterolemia in the brain and leads to neuroinflammaion. Bodovitz and klein in 1996 reported that cholesterol increases the processing of APP proteins in cell culture and also enhances brain amyloid-β accumulation. Increase level of cholesterol will increase the formation of lipid mediators of inflammation. Results shown in the table 3 and figure 1 indicates that administration of LPS on 1st,7th, 14th,and 21day of study leads to significant increase (117.4±0.95mg/dl) in cholesterol level as compared to normal mice (85.21±1.55mg/dl). Administration of SB239063 at a dose level of 5.0mg/kg from 21st to 30 days of study caused significant decrease (88.76±1.63mg/dl) in the cholesterol level. At the dose level of 2.5mg/kg SB239063 in combination with vit b12 also produce significant decrease (89.74±1.33mg/dl) in the cholesterol level but SB239063 alone produce better effect than in combination. The standard drug donepezil however has only mild effect on the cholesterol level in LPS treated mice. As we know that p38 pathways are activated by stress and inflammation. In neuroinflammation, the formation of inflammatory mediators and cytokines causes activation of p38 MAP Kinase and leads to cell stress and death. In the present study it was found that SB239063 at higher dose level is causing decrease in brain cholesterol level, which suggests that p38MAP Kinase inhibitor also reduces cholesterol synthesis in the brain and thereby decrease neuroinflammation.




***Figure 1.*** *Effect of SB239063 on the blood serum level of cholesterol in lps induced neuroinflammation in rats.*

***Table 3.*** *Effect of sb239063 on the blood serum level of cholestrol, total lipid, hdl,in lps induced neuroinflammation in rats.*

| Treatment | Cholestrol (Mg/dl) | HDL (Mg/dl) | Total Lipid (Mg/dl) |
|---|---|---|---|
| Group 1 | 85.21±1.55 | 51.13±2.94 | 0.284±0.005 |
| Group 2 | 117.4±0.9** | 24.14±1.58** | 0.31±0.005** |
| Group 3 | 88.7±1.63** | 48.55±3.098* | 0.28±0.002** |
| Group 4 | 107.1±2.04 | 34.81±2.51 | 0.299±0.004* |
| Group 5 | 89.74±1.33* | 50.13±3.95** | 0.285±0.04** |
| Group 6 | 94.26±2.58* | 46.07±2.38* | 0.294±0.003* |
| Group 7 | 106±2.77 | 38.26±1.87* | 0.290±0.013* |
| Group 8 | 109.1±2.7** | 32.86±2.18 | 0.298±0.03** |

**Effect of SB239063 and its combination with Vit B12 at different doses levels on the serum level of HDL in LPS induced neuroinflammation in rats:** Results in the table 3 and figure 2 Indicated that on administeration of LPS for 1st, 7th,14th,21st day of study caused significant decrease (24.14±1.58 mg/dl) in the level of HDL in neuroinflammed mice as compared to normal rats (51.13±2.94mg/dl). The reason why inflammation cause decrease in HDL level is still unclear. Administration of SB239063 at a dose of 5.0 mg/kg caused marked increase (48.55±3.09 mg/dl) in the level of serum HDL in LPS treated rats. The standard drug donepezil (5mg/kg) also caused significant increase (32.86±2.18mg/dl) in serum HDL level in neuroinflammed rats. Result of the study suggests that SB239063 have potential to increase the HDL level in the neurotoxic rats. Restoration of the value of HDL to normal level indicates protective effect of the treatment in neurotoxicity.At lower dose level of SB239063 of 2.5mg/kg in combination with vit b12 caused more significant increase (50.13±3.95 mg/dl) in HDL level in neuroinflammed rats as compair to SB239063 alone. HDL modulates inflammation and promotes reverse cholesterol transport. HDL cholesterol severely decreases in neuroinflammation. Oxidative stress and excess levels of active oxygen species disrupt the level of HDL in neuroinflammation. HDL is a good lipid and participates in blood cholesterol transport in the brain. Effect of SB239063 and its combination with Vit B12 at different doses levels on the serum level of total lipid in LPS induced neuroinflammation in rats.




***Figure 2.*** *effect of SB239063 on the blood serum level of total HDL in lps induced neuroinflammation in rats.*

Results shown in the table 3 and figure 3 indicates that administration of LPS on 1st,7th,14th,and 21day of study leads to significant increase (0.315±0.005 gm/dl) in total lipid level as compared to normal rat (0.284±0.005 g/dl). Administration of SB239063 at a dose level of 5.0mg/kg from 21st to 30 days of study caused significant decrease (0.282±0.002g/dl) in the total lipid level. At the dose level of 4.5mg/kg SB239063 in combination with vit b12 also produce significant decrease (0.285±0.004 g/dl) in the total lipid level but SB239063 alone produce better effect than in combination. The standard drug donepezil however has only mild effect on the total lipid level in LPS treated rats.




***Figure 3.*** *Effect of sb239063 on the blood serum level of total lipid in lps induced neuroinflammation in rats.*

## Discussion

A significant amount of evidence suggests that the p38 MAPK (mitogen activated protein kinase) signaling cascade play a crucial role in neurodegenerative diseases.The MAPKs are a specific class of serine/threonine kinases that respond to extracellular signals such as growth factors, mitogens and cellular stress and mediate proliferation, differentiation and cell survival in mammalian cells. There are distinct groups of MAPKs within mammalian cells including p38 MAPK, ERKs and JNKs [16].In the CNS, activation of the p38 MAPK pathway constitutes a key step in the development of neuroinflammation. Inflammatory stimuli bind to receptors of the cell surface triggering intracellular signal transduction pathways such as the nuclear factor (NFkB) pathway and the MAPK pathways [17,18]. Intracellular p38 MAP kinase gets activated and profoundly modulates somatic inflammatory responses. MAPK p38 signaling controls the expression of adhesion molecules, cytokines and chemokines, and a variety of other factors that mediate and control the inflammatory process. There is abounding evidence that neuroinflammation plays a major role in the pathogenesis of neurodegenration. Key cellular signaling events such as subsequent activation of mitogen activated protein kinase (MAPK) regulate

neuroinflammation, neuronal survival and synaptic activity [15]. Irregularities in p38 MAPK signaling in neuronal cells have been associated with diseases linked with neuroinflammatory processes where persistent inflammatory stimuli such as chronic microglial activation have a damaging rather than a protective effect [19]. Prolonged and sustained activation of glial cells can result in an exaggerated inflammatory response that causes neuronal cell death through the elevated release of proinflammatory cytokines, which have a potential neurotoxic effect leading to neurodegeneration [20,21]. This work outlines the rationale for developing therapeutics strategies against MAPK signalling network identifying them as novel therapeutic target for limiting neuroinflammtion. Moreover, resent studies suggest that cyanocobalamine act as a cofactor in myelin formation and has important immunomodulatory and neurotropic effect. Our result demonstrates that administration of LPS induced neuroinflammation leads to memory impairment and variation of various biochemical parameters. These finding replicates the result of previous studies that demonstrate that activation of immune system by LPS as well as other immune challenges induced anxiogenic, reduction in locomotor activity and social activity. In our present study we have demonstrate the inhibition of P38 mitogen activated protein kinase (MAPK) pathway in animals by their suppressed locomotion and anxiogenic activity which produced required effects. In our study further studies are needed to demonstrate the histopathological changes in different parts of the brain.

## Conclusions

Our study suggests that P38 MAPK inhibiter (SB239063) and cyanocobalamine attenuated neuroinflammation induced by intraperitoniel endotoxin instillation in rats.

## References


1. Bachstetter AD, Van Eldik LJ. The p38 MAP kinase family as regulators of proinflammatory cytokine production in degenerative diseases of the CNS. Aging and disease. 2010;1(3):199.
2. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochemical Journal. 2010;429(3): 403-17.
3. Rathod R, Khaire A, Kale A, et al. A combined supplementation of vitamin B12 and n-3 polyunsaturated fatty acids across two generations improves nerve growth factor and vascular endothelial growth factor levels in the rat hippocampus. Neuroscience. 2016; 339:376-84.
4. Field MS, Kamynina E, Chon J, et al. Nuclear folate metabolism. Annual review of nutrition. 2018; 38:219-43.
5. Gröber U, Kisters K, Schmidt J. Neuroenhancement with vitamin B12—underestimated neurological significance Nutrients. 2013;5(12):5031-45.
6. Hobbenaghi R, Javanbakht J, Hosseini E, et al. Neuropathological and neuroprotective features of vitamin B12 on the dorsal spinal ganglion of rats after the experimental crush of sciatic nerve: an experimental study (Retraction of vol 8, pg 123, 2013). Diagnostic Pathology. 2016 Nov 2;11.
7. Chan W, Almasieh M, Catrinescu MM, et al. Cobalamin-associated superoxide scavenging in neuronal cells is a potential mechanism for vitamin B12–deprivation optic neuropathy. The American journal of pathology. 2018 Jan 1;188(1):160-72.
8. Horiuchi K, Amizuka N, Takeshita S, et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor β. Journal of bone and mineral research. 1999 Jul; 14(7):1239-49.
9. Boehm JC, Smietana JM, Sorenson ME, Garigipati RS, Gallagher TF, Sheldrake PL, Bradbeer J, Badger AM, Laydon JT, Lee JC, Hillegass LM. 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. Journal of medicinal chemistry. 1996 Sep 27;39(20):3929-37.
10. Lee JC, Young PR. The role of the MAP kinase homologue, CSBP in LPS and cytokine signaling. J Leukoc Biol. 1996; 59:152-7.
11. Kumar S, McDonnell PC, Gum RJ, et al. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochemical and biophysical research communications. 1997;235(3):533-8.
12. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, Huddleston MJ. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. Journal of Biological Chemistry. 1997; 272(18):12116-21.
13. Ben Levy R, Hooper S, Wilson R, et al. Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Current Biology. 1998 Sep 24;8(19):1049-57.
14. Lee JC, Young PR. Role of CSBP/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. Journal of Leukocyte Biology. 1996;59(2):152-7.
15. Ramesh G. Novel therapeutic targets in neuroinflammation and neuropathic pain. Inflammation and cell signaling. 2014; (3).
16. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochemical Journal. 2010429(3): 403-17.
17. Ono K, Han J. The p38 signal transduction pathway activation and function. Cellular signalling. 2000;12(1):1-3.
18. Sanjay K, Jeffrey B, Lee JC. P38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003;2(9): 717-26.
19. Streit WJ, Mrak RE, Griffin WS. Microglia and neuroinflammation: a pathological perspective. Journal of neuroinflammation. 2004;1(1):1-4.
20. Chao CC, Hu S, Peterson PK, et al. Critical reviews in neurobiology.1995;9(2-3):189.

21. Skaper SD. The brain as a target for inflammatory processes and neuroprotective strategies. Ann N Y Acad Sciences. 2007;1122:23-34.

## *Correspondence to:

Dr. Ashish kumar verma

Department of pharmacology

Teerthanker Mahaveer College of pharmacy

Moradabad

India

E-mail: ashishkumarvrm@gmail.com